Update on Strategic Management of Advanced GIST

Abstract 

Gastrointestinal stromal tumors (GISTs) originating from the interstitial cells of Cajal are mesenchymal tumors of the gastrointestinal tract and have been found to harbor c-KIT mutations and KIT (CD117) expression since 1998. Later, PDGFRA mutations other drive mutations were identified in GISTs. In order to provide clinical useful information in diagnostic and therapeutic strategies of GISTs, we plan to comprehensively review the molecular markers and genetics of GISTs. Successful treatment in GISTs prolongs the survival of GIST patients and turns GISTs to become stable. Recently, the approval of ripretinib, an emerging new generation of board spectrum TKI, would be the effective treatment for GISTs resistant to imatinib/sunitinib/regorafenib based on the data of the INVICTUS trial. and KIT/PDGFRA-WT GISTs will be the challenge for GISTs.